Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Trevena_Inc> ?p ?o. }
Showing items 1 to 57 of
57
with 100 items per page.
- Trevena_Inc abstract "Trevena Inc a clinical stage biopharmaceutical company, headquartered in King of Prussia, PA, and is the leader in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. Trevena was founded with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's innovative approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. In 2008, the company raised $25 Million in a Series A financing round led by Alta Partners, Polaris Ventures, New Enterprise Associates, Healthcare Ventures, and Yasuda Economic Development Corporation. Trevena was named one of the top 15 US startups of 2008 by Business Week. The company raised an additional $35 million USD in a B round of venture financing in the summer of 2010.Trevena's lead program, TRV027 for acute heart failure, targets the angiotensin receptor utilizing beta-arrestin bias, an approach that has shown numerous beneficial cardiovascular and renal actions in preclinical species. Trevena completed Phase I clinical trials in 2010. Phase 2 clinical trials on TRV027 began in the spring of 2011.Trevena is also developing TRV130, a G protein-biased ligand for the intravenous treatment of acute moderate-to-severe post-operative pain. The Phase I first-in-human clinical trial of TRV130 is complete. The drug was safe and generally well-tolerated in this study, with pharmacodynamic effects recapitulating its exciting preclinical profile. The next clinical study of TRV130 will investigate analgesic efficacy and tolerability, and will include intravenous morphine, a gold-standard post-operative analgesic, as a comparator. Trevena’s expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. In addition to TRV027, Trevena’s pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, and Parkinson’s disease. In early 2009, Trevena entered into a collaborative agreement with Ligand Pharmaceuticals to identify biased ligands at numerous GPCRs from a large, diverse chemical library. Later that year, Trevena received a competitively awarded American Recovery and Reinvestment Act Grand Opportunities Grant, spanning two years and funding $7.65 million USD of research. The company has disclosed specific interests in the mu Opioid receptor and kappa Opioid receptor. In 2011, Treveva received another NIH grant as part of the NIH Blueprint Neurotherapeutics Network, potentially worth up to $10M USD, to support preclinical development of a delta opioid receptor biased ligand for major depressive disorder. Trevena has received funding from the Michael J. Fox Foundation to explore the potential for delta opioid receptor biased ligands to treat Parkinson's disease.".
- Trevena_Inc locationCity King_of_Prussia,_Pennsylvania.
- Trevena_Inc locationCountry United_States.
- Trevena_Inc numberOfEmployees "28".
- Trevena_Inc thumbnail Trevena-logo.gif?width=300.
- Trevena_Inc type Public_company.
- Trevena_Inc wikiPageExternalLink www.trevenainc.com.
- Trevena_Inc wikiPageExternalLink www.trevenainc.com.
- Trevena_Inc wikiPageID "26760758".
- Trevena_Inc wikiPageRevisionID "602533003".
- Trevena_Inc hasPhotoCollection Trevena_Inc.
- Trevena_Inc homepage www.trevenainc.com.
- Trevena_Inc industry "Biotechnology / Pharmaceutical".
- Trevena_Inc keyPeople "Maxine Gowen , Michael Lark".
- Trevena_Inc locationCity King_of_Prussia,_Pennsylvania.
- Trevena_Inc locationCountry United_States.
- Trevena_Inc logo "150".
- Trevena_Inc name "Trevena Inc".
- Trevena_Inc numEmployees "28".
- Trevena_Inc type Public_company.
- Trevena_Inc subject Category:Biotechnology_companies_of_the_United_States.
- Trevena_Inc subject Category:Companies_based_in_Pennsylvania.
- Trevena_Inc subject Category:Companies_listed_on_NASDAQ.
- Trevena_Inc subject Category:Pharmaceutical_companies_of_the_United_States.
- Trevena_Inc subject Category:Privately_held_companies_based_in_Pennsylvania.
- Trevena_Inc type Abstraction100002137.
- Trevena_Inc type BiotechnologyCompaniesOfTheUnitedStates.
- Trevena_Inc type CompaniesBasedInPennsylvania.
- Trevena_Inc type Company108058098.
- Trevena_Inc type DrugCompany108002578.
- Trevena_Inc type Group100031264.
- Trevena_Inc type Institution108053576.
- Trevena_Inc type Organization108008335.
- Trevena_Inc type PharmaceuticalCompaniesOfTheUnitedStates.
- Trevena_Inc type PrivatelyHeldCompaniesBasedInPennsylvania.
- Trevena_Inc type SocialGroup107950920.
- Trevena_Inc type YagoLegalActor.
- Trevena_Inc type YagoLegalActorGeo.
- Trevena_Inc type YagoPermanentlyLocatedEntity.
- Trevena_Inc type Agent.
- Trevena_Inc type Company.
- Trevena_Inc type Organisation.
- Trevena_Inc type Organization.
- Trevena_Inc type Agent.
- Trevena_Inc type SocialPerson.
- Trevena_Inc type Thing.
- Trevena_Inc comment "Trevena Inc a clinical stage biopharmaceutical company, headquartered in King of Prussia, PA, and is the leader in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. Trevena was founded with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman.".
- Trevena_Inc label "Trevena Inc".
- Trevena_Inc sameAs m.0bmh9xs.
- Trevena_Inc sameAs Q7838954.
- Trevena_Inc sameAs Q7838954.
- Trevena_Inc sameAs Trevena_Inc.
- Trevena_Inc wasDerivedFrom Trevena_Inc?oldid=602533003.
- Trevena_Inc depiction Trevena-logo.gif.
- Trevena_Inc homepage www.trevenainc.com.
- Trevena_Inc isPrimaryTopicOf Trevena_Inc.
- Trevena_Inc name "Trevena Inc".